Dr. Sundas Khan
Overview
Sundas Khan is a Hematologist and an Oncologist in Lancaster, Pennsylvania. Dr. Khan is rated as an Experienced provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are DICER1 Syndrome, HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, and Familial Colorectal Cancer. Dr. Khan is currently accepting new patients.
Her clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE PDP
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- OTHER MEDICARE PART D
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2102 Harrisburg Pike, Lancaster, PA 17601
Additional Areas of Focus
Dr. Khan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Reading Hospital
Radhakrishnan Ramchandren is a Hematologist and a Hematologist Oncology provider in West Reading, Pennsylvania. Dr. Ramchandren is rated as an Elite provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Ramchandren is currently accepting new patients.
University Of Penn-Medical Group
Jakub Svoboda is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Svoboda is rated as an Elite provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.
Johns Hopkins University
Richard Ambinder is an Oncologist in Baltimore, Maryland. Dr. Ambinder is rated as an Elite provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Ambinder is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- DICER1 SyndromeDr. Khan isAdvanced. Learn about DICER1 Syndrome.
- Experienced
- Atypical Hemolytic Uremic Syndrome (aHUS)
- BRCA Positive Breast CancerDr. Khan isExperienced. Learn about BRCA Positive Breast Cancer.
- D-Plus Hemolytic Uremic SyndromeDr. Khan isExperienced. Learn about D-Plus Hemolytic Uremic Syndrome.
- Familial Colorectal CancerDr. Khan isExperienced. Learn about Familial Colorectal Cancer.
- Hemolytic-Uremic SyndromeDr. Khan isExperienced. Learn about Hemolytic-Uremic Syndrome.
- HER2 Negative Breast CancerDr. Khan isExperienced. Learn about HER2 Negative Breast Cancer.